<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAM</journal-id>
<journal-id journal-id-type="hwp">sptam</journal-id>
<journal-title>Therapeutic Advances in Medical Oncology</journal-title>
<issn pub-type="ppub">1758-8340</issn>
<issn pub-type="epub">1758-8359</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1758834012446008</article-id>
<article-id pub-id-type="publisher-id">10.1177_1758834012446008</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Dimou</surname><given-names>Anastasios</given-names></name>
<aff id="aff1-1758834012446008">Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Syrigos</surname><given-names>Konstantinos N.</given-names></name>
<aff id="aff2-1758834012446008">3rd Department of Medicine, Oncology Unit, University of Athens Medical School, Athens, Greece</aff>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Saif</surname><given-names>Muhammad Wasif</given-names></name>
<aff id="aff3-1758834012446008">Columbia University College of Physicians and Surgeons and Pancreas Center, New York Presbyterian Hospital, New York, NY, USA</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-1758834012446008"><email>wasifcolumbia@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>4</volume>
<issue>5</issue>
<fpage>271</fpage>
<lpage>279</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Pancreatic cancer has historically proven resistant to anticancer agents. On the one hand, drugs might be more efficient if higher levels could be achieved at the tumor site rather than the normal tissues. On the other hand, the thick stroma and the relative absence of abundant vessels may account at least partially for the failure of successive clinical trials to demonstrate effective treatments in this type of malignancy. In this context, the development and testing in clinical trials of treatment strategies that aim to optimize drug delivery is an important target in improving the prognosis of patients with pancreatic cancer.</p>
</abstract>
<kwd-group>
<kwd>chemotherapy</kwd>
<kwd>drug delivery</kwd>
<kwd>folfirinox</kwd>
<kwd>gemcitabine</kwd>
<kwd>pancreatic cancer</kwd>
<kwd>resistance</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1758834012446008" sec-type="intro">
<title>Introduction</title>
<p>Pancreatic adenocarcinoma remains one of the most difficult to handle malignancies. Most patients are diagnosed with inoperable disease and their treatment options are limited [<xref ref-type="bibr" rid="bibr16-1758834012446008">Hidalgo, 2010</xref>]. Few clinical trials have proven that certain drugs can improve prognosis in this setting: patients treated with gemcitabine survive for 6 months on average whereas erlotinib adds minimal benefit when combined with gemcitabine [<xref ref-type="bibr" rid="bibr4-1758834012446008">Berlin <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr40-1758834012446008">Senderowicz <italic>et al</italic>. 2007</xref>]. Recently, the combination of 5-fluorouracil (5-FU), leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) proved superior to standard regimens at the cost of substantial toxicity [<xref ref-type="bibr" rid="bibr9-1758834012446008">Conroy <italic>et al</italic>. 2011</xref>]. However, the majority of studies have failed to provide an efficient treatment paradigm.</p>
<p>Systemic regimens use tumor vessels to reach tumor cells and become effective. In this regard, besides their numerous mechanisms to overcome treatment effects, tumors grow to be viable in hypoxic conditions and less dependent on their vascular beds as part of their evolution process [<xref ref-type="bibr" rid="bibr7-1758834012446008">Brahimi-Horn <italic>et al</italic>. 2007</xref>]. At the absence of abundant vessels, administered drugs cannot access their targets easily. Pancreatic adenocarcinoma cells in particular often appear to grow within a fibrotic, abundant, and poorly perfused stroma. Thus, compounds are less likely to accumulate close to such cells, independently of their targeting specificity or their antitumor potential [<xref ref-type="bibr" rid="bibr30-1758834012446008">Neesse <italic>et al</italic>. 2011</xref>].</p>
<p>Conventional chemotherapy halts cell division or even demonstrates toxic activity preferentially on cells that proliferate fast. On the basis that tumor cells divide more rigorously than cells in normal tissues, such regimens have a tumor-specific effect to some extent. Furthermore, novel treatment modalities are designed to target nearly unique features expressed mainly in specific tumors. Nevertheless, both conventional chemotherapy and targeted therapies cause a series of dose-limiting adverse events because of activity on normal tissues. Optimization of drug specificity can therefore render larger accumulation in the tumor area and achieve a more preferable effect to toxicity ratio.</p>
<p>Taking into account the need for effective treatment strategies that spare the normal tissue in patients with pancreatic cancer, tumor-specific delivery of compounds becomes relevant. Advances in nanotechnology have provided potential delivery systems that might add clinical benefit to existing standard treatments. However, manipulation of the tumor microenvironment holds promise for effective treatments to overcome the stromal barrier. This review aims to illustrate the existing evidence and the rationale for incorporating drug delivery optimization systems in the arms of clinical trials in pancreatic cancer.</p>
</sec>
<sec id="section2-1758834012446008">
<title>Rationale for using nanoparticles in pancreatic cancer</title>
<p>Hydrophobicity can limit the effect a drug might manifest against a tumor since efficient antitumor activity requires delivery through aqueous compartments. Addition of various excipients is currently used to provide hydrophilic properties. However, as in the case of paclitaxel, excipients are linked to severe hypersensitivity reactions. An alternative route to improve the efficiency of the delivery systems is the use of nanoparticles.</p>
<p>Nanoparticles are materials less than 100 nm in size. They share size-specific physicochemical properties which are distinct from larger materials. In medicine, both inorganic and polymeric nanoparticles have been used for diagnostic and treatment purposes [<xref ref-type="bibr" rid="bibr46-1758834012446008">Youns <italic>et al</italic>. 2011</xref>]. Modification of their composition provides a broad range of different options, including simple passive vehicles, active compounds and molecule-specific targeting entities. They are biocompatible and allow the optimization of half life, biodistribution and water solubility of anticancer agents. Most of the nanoparticles are ‘PEGylated’ in that they are modified to include poly-ethylene-glycol (PEG) in their surface. PEGylation has proven the best among other nanoparticle modifications in adding stability along with mediating escape from the reticuloendothelial system [<xref ref-type="bibr" rid="bibr35-1758834012446008">Prencipe <italic>et al</italic>. 2009</xref>].</p>
<p>Tumor vessels have bigger fenestration pores than normal vasculature [<xref ref-type="bibr" rid="bibr47-1758834012446008">Yuan <italic>et al</italic>. 1995</xref>]. Furthermore, they are wider and they lack normal smooth muscle layers. Thus, they respond to various vasoconstriction stimuli with a hypertension-mediated passive dilatation instead of vasoconstriction [<xref ref-type="bibr" rid="bibr29-1758834012446008">Nagamitsu <italic>et al</italic>. 2009</xref>]. In addition, tumors’ lymphatic drainage network is inadequate to clear macromolecules that enter in the tumor area [<xref ref-type="bibr" rid="bibr20-1758834012446008">Ji, 2005</xref>]. The unique features of tumor angiogenesis and lymphangiogenesis contribute to accumulation of systemically administered macromolecular compounds, a phenomenon better known as enhanced permeability and retention effect (EPR; <xref ref-type="fig" rid="fig1-1758834012446008">Figure 1</xref>) [<xref ref-type="bibr" rid="bibr27-1758834012446008">Maeda, 2001</xref>]. When the size of such a drug exceeds a certain threshold, the drug gathers in the tumor area through the abnormally enlarged tumor vessel openings. However, they spare normal tissues since they cannot go through the narrow openings of normal vessels. Scant and defective lymphatics cannot transfer the drug from its initial deposition in the tumor to a different compartment. Besides, increased size prevents rigorous renal clearance and results in prolonged circulation. Taken together these features lead to accumulation of macromolecular compounds inside tumors. The size threshold for the EPR effect to occur has been defined as 40 kDa [<xref ref-type="bibr" rid="bibr39-1758834012446008">Seki <italic>et al</italic>. 2009</xref>]. The entrapment of an active drug in the tumor can be an attractive treatment strategy as it allows higher and potentially more effective dosage schemes while sparing the normal tissues.</p>
<fig id="fig1-1758834012446008" position="float">
<label>Figure 1.</label>
<caption>
<p>Illustration of the enhanced permeability and retention effect. Nanoparticles can easily go through the pores of the leaky tumor vasculature, while they do not have access to healthy tissues with normal vessels (top panel). In contrast, conventional drug delivery results in accumulation of the drug in both the tumor and the healthy tissues, giving rise to systemic adverse events (bottom panel).</p>
</caption>
<graphic xlink:href="10.1177_1758834012446008-fig1.tif"/>
</fig>
</sec>
<sec id="section3-1758834012446008">
<title>Nanoparticles can optimize delivery of conventional cytotoxics</title>
<p><xref ref-type="fig" rid="fig2-1758834012446008">Figures 2(a)</xref> and <xref ref-type="fig" rid="fig2-1758834012446008">(b)</xref> show a liposomic nanoparticle basic structure and a copolymer-based nanoparticle.</p>
<fig id="fig2-1758834012446008" position="float">
<label>Figure 2.</label>
<caption>
<p>(a) Liposomic nanoparticle basic structure. A lipid layer forms a micelle which exerts hydrophilic properties and its size is within the nanotechnology spectrum. Antibodies or other peptides can boost the particle’s specificity to tumor epitopes like epidermal growth factor receptor. (b) Copolymer-based nanoparticle. In this system the drug, shown here in red, is covalently bound to a polymer. The resulting nanoparticle is water soluble and has the appropriate size to accumulate in the tumor area. Tumor epitope specific peptides can be added to this basic scheme.</p>
</caption>
<graphic xlink:href="10.1177_1758834012446008-fig2.tif"/>
</fig>
<p>Paclitaxel is a hydrophobic compound and is traditionally administered with castor oil so that it becomes solvent in aqueous media [<xref ref-type="bibr" rid="bibr37-1758834012446008">Rischin <italic>et al</italic>. 1996</xref>]. A different approach is based on linking the active compound to albumin and forming albumin-based, hydrophilic nanoparticles [<xref ref-type="bibr" rid="bibr11-1758834012446008">Di Costanzo <italic>et al</italic>. 2009</xref>]. Pretreatment is not required to avoid hypersensitivity reactions with nab-paclitaxel. It has been tried in a phase I trial in variable tumors, including pancreatic cancer, and it has demonstrated an acceptable toxicity profile [<xref ref-type="bibr" rid="bibr8-1758834012446008">Chien <italic>et al</italic>. 2009</xref>]. Data for paclitaxel efficacy in pancreatic cancer are limited; however, nab-paclitaxel might be superior to paclitaxel due to better pharmacokinetics and more favorable accumulation in the tumor. Data from a phase I trial [<xref ref-type="bibr" rid="bibr12-1758834012446008">Drengler <italic>et al</italic>. 2008</xref>] of nab-paclitaxel plus gemcitabine and a phase II trial [<xref ref-type="bibr" rid="bibr18-1758834012446008">Hosein <italic>et al</italic>. 2010</xref>] of nab-paclitaxel after gemcitabine failure in advanced pancreatic cancer are promising. In particular, in the phase II trial patients although refractory to gemcitabine had an overall median survival of 7.3 months and progressed after a median time of 1.3 months. In addition, a great number of phase I and II clinical trials are testing nab-paclitaxel in various combinations and settings of pancreatic cancer. A recently published phase I/II study tested the safety and efficacy of nab-paclitaxel in combination with gemcitabine in the first-line setting of advanced pancreatic cancer [<xref ref-type="bibr" rid="bibr42-1758834012446008">Von Hoff <italic>et al</italic>. 2011</xref>]. Neutropenia was the dose-limiting toxicity and median survival was 12.2 months. Interestingly, expression of secreted protein acidic and rich in cysteine in the stroma was associated with higher response rate. In the same study the combination of gemcitabine with nab-paclitaxel achieved stromal depletion and higher gemcitabine concentration in the tumor area compared with gemcitabine alone in xenograft models in mice.</p>
<p>Curcumin has demonstrated anticancer activity in a panel of different tumors <italic>in vitro</italic> [<xref ref-type="bibr" rid="bibr1-1758834012446008">Altenburg <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr24-1758834012446008">Lu <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr49-1758834012446008">Zhang <italic>et al</italic>. 2010</xref>]. Curcumin has been shown to increase apoptosis and block nuclear factor κB in pancreatic cancer cells [<xref ref-type="bibr" rid="bibr21-1758834012446008">Jutooru <italic>et al</italic>. 2010</xref>]. Nonetheless, there is a gap between the <italic>in vitro</italic> promising data and the efficiency of the compound <italic>in vivo</italic> due to its hydrophobicity and subsequent impractical pharmacokinetic profile [<xref ref-type="bibr" rid="bibr14-1758834012446008">Garcea <italic>et al</italic>. 2004</xref>]. Recently, a polymeric nanoparticle containing curcumin has been developed [<xref ref-type="bibr" rid="bibr6-1758834012446008">Bisht <italic>et al</italic>. 2007</xref>]. This has been shown to be a promising ‘nanocurcumin’ that demonstrates similar antitumor activity against pancreatic cancer cells and subcutaneous and orthotopic xenografts. In addition, its effect is additive to the effect of gemcitabine. Furthermore, another study has shown that curcumin forms nanoparticles in the presence of rubusoside that are active against breast colon and pancreatic cancer cell lines [<xref ref-type="bibr" rid="bibr48-1758834012446008">Zhang <italic>et al</italic>. 2001</xref>]. The effect of nanocurcumin has not been evaluated in clinical trials as yet but might be a reasonable option given the anticancer activity of curcumin combined with the favorable nanotechnology pharmacokinetics.</p>
<p>CPT-11 has demonstrated significant efficacy against pancreatic cancer as part of the FOLFIRINOX scheme. SN38 is the active metabolite of CPT11 responsible for the antitumor activity and the adverse events. Saito and colleagues have tested the efficacy of NK012, a polymeric micelle that contains SN38, in the setting of xenograft models generated by hypervascular and hypovascular pancreatic tumors [<xref ref-type="bibr" rid="bibr38-1758834012446008">Saito <italic>et al</italic>. 2008</xref>]. Interestingly, they reported that NK012 achieved a better and more durable release of SN38 in the tumor area compared with CPT-11 in both xenograft models. In their experiments, NK012 but not CPT-11 resulted in eradication of all the tumors treated. Based on this study, nanoparticle-based SN38 might lead to specific accumulation of the drug in the tumor area even in relatively avascular tumors surrounded by a thick stroma. Another possible modality of more effective irinotecan delivery is the liposomic preparation of CPT-11 or PEP02. In the interim analysis of a phase II study PEP02 monotherapy in metastatic gemcitabine refractory pancreatic cancer achieved 3-month survival of 74%. The most common grade 3–4 side effects were fatigue, neutropenia, nausea, vomiting and diarrhea [<xref ref-type="bibr" rid="bibr23-1758834012446008">Ko <italic>et al</italic>. 2011</xref>].</p>
</sec>
<sec id="section4-1758834012446008">
<title>Nanoparticle-based delivery of small interfering RNAs</title>
<p>Gene therapy has been a promising field in the therapeutics of human tumors. Small interfering RNA (siRNA) refers to small RNA molecules that can effectively target and suppress specific messenger RNAs (mRNAs). This technology can be employed to modify gene expression at the mRNA level once it is effectively delivered in the target cells and avoids endosomal entrapment and degradation. Nanotechnology provides a range of candidate carriers in this regard. Calcium precipitates have been used in the past for nucleic acid delivery inside the cells [<xref ref-type="bibr" rid="bibr13-1758834012446008">Fasbender <italic>et al</italic>. 1998</xref>]. Pittella and colleagues have created a complex of PEG, charge conversional polymer (CCP), and calcium precipitates as stable nanoparticles to bind polyanions and siRNAs [<xref ref-type="bibr" rid="bibr34-1758834012446008">Pittella <italic>et al</italic>. 2011</xref>]. PEG provides colloidal stability whereas CCP inhibits endosomal entrapment. The investigators proved that this system can effectively deliver siRNA against vascular endothelial growth factor in pancreatic cancer cells <italic>in vitro</italic>. Although primitive, this work has created an option for siRNA delivery which needs to be validated in higher organized systems.</p>
<p>Other groups have employed nanotechnology to effectively deliver siRNAs in pancreatic cancer models. In one of these studies, mesoporous nanoparticles (MSNPs) were synthesized from tetraethyl orthosilicate and a micellar template. Their large surface allows delivery of drugs in larger amounts [<xref ref-type="bibr" rid="bibr44-1758834012446008">Xia <italic>et al</italic>. 2009</xref>]. The addition of polyethyleneimine polymer made the surface of MSNPs cationic and favorable for attaching nucleic acids like siRNAs. A second group successfully used poly lactic- co -glycolic acid (PLGA) poloxamer nanoparticles for delivering siRNA against methyl-CpG binding domain protein 1 in pancreatic cancer cells [<xref ref-type="bibr" rid="bibr25-1758834012446008">Luo <italic>et al</italic>. 2009</xref>]. Cell proliferation was then inhibited and apoptosis was activated. Finally, in a third study antihuman epidermal growth factor receptor 2 siRNA was effectively delivered and inhibited tumor growth with an immunoliposome-based nanoparticle in pancreatic cancer models <italic>in vitro</italic> and <italic>in vivo</italic> [<xref ref-type="bibr" rid="bibr17-1758834012446008">Hogrefe <italic>et al</italic>. 2006</xref>]. This system specifically targeted tumor cells with the addition of a single chain transferrin specific antibody. Again, these interesting approaches require further experimentation before any conclusions regarding their efficacy in pancreatic cancer can be drawn.</p>
</sec>
<sec id="section5-1758834012446008">
<title>Nanoparticles with attached epitope-specific targeting molecules</title>
<p>Pancreatic cancer specificity of nanotechnology-based treatment platforms can be optimized by the attachment of antibodies to nanoparticle surface, able to recognize and bind epitopes uniquely expressed in pancreatic adenocarcinoma. In this context, epidermal growth factor receptor (EGFR) is often present and abundant in pancreatic cancer cells [<xref ref-type="bibr" rid="bibr10-1758834012446008">Dancer <italic>et al</italic>. 2007</xref>]. Cetuximab is an EGFR-specific antibody which inhibits the receptor dimerization and activation. Cetuximab can be conjugated to nanoparticles carrying chemotherapy drugs and then exert receptor internalization upon binding to EGFR in a distinct pharmacodynamic fashion compared with cetuximab alone [<xref ref-type="bibr" rid="bibr5-1758834012446008">Bhattacharyya <italic>et al</italic>. 2010</xref>]. In a study that illustrates this rationale, gemcitabine was effectively delivered with cetuximab-coated gold nanoparticles to pancreatic cancer cell lines <italic>in vitro</italic> and to pancreatic cancer xenografts <italic>in vivo</italic> [<xref ref-type="bibr" rid="bibr33-1758834012446008">Patra <italic>et al</italic>. 2008</xref>]. Uptake of the nanoconjugates is then proportional to EGFR presence on the cancer cells. A different approach that combines radiofrequency thermal effects with cetuximab-coated gold nanoparticles has been described [<xref ref-type="bibr" rid="bibr15-1758834012446008">Glazer <italic>et al</italic>. 2010</xref>]. In this strategy, gold nanoparticles accumulate in the tumor cells that express EGFR and mediate the radiofrequency thermal effects <italic>in vitro</italic> and <italic>in vivo</italic>. Cell viability was reduced only in cell lines that expressed EGFR rather than cocultured adjacent cell lines that did not express the receptor. In addition, this approach was able to reduce tumor growth in xenograft models using cetuximab or an antibody against mucin 1 (MUC1) as a targeting molecule.</p>
<p>Besides EGFR and MUC1, other pancreatic-cancer-specific epitopes have been targeted with antibodies and other molecules conjugated with nanoparticles in preclinical models: a half antibody that recognizes carcino-embryonic antigen (CEA) as part of a lipid-polymeric hybrid nanoparticle has been described and shown to specifically target CEA-overexpressing pancreatic cancer cells [<xref ref-type="bibr" rid="bibr19-1758834012446008">Hu <italic>et al</italic>. 2010</xref>]. Pentagastrin and decagastrin have been conjugated to pegylated calcium phosphosilicate nanoparticles and target orthotopic mouse pancreatic cancer models that express gastrin receptors [<xref ref-type="bibr" rid="bibr2-1758834012446008">Barth <italic>et al</italic>. 2010</xref>]. In another study, a nanoparticle containing the chemotherapeutic agent doxorubicin was targeted against integrin avβ3, which is preferentially expressed in some areas of the tumor vasculature [<xref ref-type="bibr" rid="bibr28-1758834012446008">Murphy <italic>et al</italic>. 2008</xref>]. In these experiments, a 15-fold increase in apoptosis was reported in the areas of the tumor where the targeted integrin was expressed in the adjacent vessels. Last but not least, Luo and colleagues described LyP-1, which is a nine-amino-acid peptide that homes to lymphatic vessels of the tumors and lymph node metastases, conjugated nanoparticles and their ability to accumulate in the lymph node metastases of pancreatic cancer mouse models [<xref ref-type="bibr" rid="bibr26-1758834012446008">Luo <italic>et al</italic>. 2010</xref>].</p>
<p>A slightly different and interesting approach has been proposed by Weissleder and colleagues [<xref ref-type="bibr" rid="bibr43-1758834012446008">Weissleder <italic>et al</italic>. 2005</xref>]. Specifically, this group has created a library of over a hundred fluorescent magnetic nanoparticles conjugated with small molecules like amines and alcohols. Then they screened pancreatic cancer cells against this library and isolated the small molecules that would preferentially target these cells but not macrophages or endothelial cells. In this paradigm, the specificity of the nanoparticles is based on nonspecific small molecules rather than antibodies or other entities specific to tumor antigens.</p>
</sec>
<sec id="section6-1758834012446008">
<title>Stromal targeting therapies</title>
<p>Since pancreatic cancer cells are surrounded by a thick, poorly perfused stroma which halts penetration of otherwise effective treatments, it is reasonable to incorporate a stroma depleting agent into the therapeutic plan of patients with pancreatic adenocarcinoma. The basic idea that reducing the size of the stroma will expose the tumor to chemotherapy is further supported by studies that illustrate the active role of the tumor microenvironment in the biology of pancreatic cancer. In this regard it has been shown that hedgehog signaling from the pancreatic cancer cells activates the hedgehog pathway in the adjacent stroma rather than the cancer cells themselves [<xref ref-type="bibr" rid="bibr45-1758834012446008">Yauch <italic>et al</italic>. 2008</xref>]. The hedgehog pathway has been linked to the biology of the cancer stem cells and mediates important aspects of the molecular conversation between the pancreatic cancer cells and the stromal cells. While this interaction is only partially understood and research on this topic is ongoing, it has been shown that inhibition of the hedgehog pathway in pancreatic cancer mouse models enhances the formation of blood vessels in poorly vascularized tumors and decreases their stromal component [<xref ref-type="bibr" rid="bibr31-1758834012446008">Olive <italic>et al</italic>. 2009</xref>]. Taken together these effects result in better distribution of active anticancer compounds in the tumor area which would not have otherwise access to the tumor cells. These experiments support the notion of combining hedgehog inhibitors with other anticancer drugs. Indeed, a number of clinical trials based on this rationale are ongoing in pancreatic cancer. For example, IPI-926 an inhibitor of Smoothened, which is a molecule in the hedgehog pathway, was recently reported to show some activity and acceptable toxicity in a phase 1b trial [<xref ref-type="bibr" rid="bibr36-1758834012446008">Richards <italic>et al</italic>. 2011</xref>] in pancreatic cancer whereas the hedgehog inhibitor GDC-0449 was safe in a phase I trial [<xref ref-type="bibr" rid="bibr32-1758834012446008">Palmer <italic>et al</italic>. 2011</xref>]. More mature data from these trials and larger trials will clarify further the role of this strategy in the treatment of pancreatic cancer.</p>
<p>Likewise, with hedgehog signaling, other stromal-depleting strategies have been reported in mouse models. Specifically, iRGD is a tumor-penetrating peptide which has been conjugated to several anticancer drugs in the past. Sugahara and colleagues have shown that this peptide can increase the permeability and the vascularity of pancreatic cancer models when administered without prior conjugation to any other agent [<xref ref-type="bibr" rid="bibr41-1758834012446008">Sugahara <italic>et al</italic>. 2010</xref>]. This is important since conjugation may alter the physicochemical properties of a drug and therefore its efficacy. In their study, Sugahara and colleagues proved that iRGD optimized the penetration of several drugs in the pancreatic cancer area, including small molecules, nanocarriers, and monoclonic antibodies. In another study, Kano and colleagues examined the effect of inhibiting transforming growth factor β (TGFβ) signaling with a low-dose TGFβ type 1 receptor inhibitor in pancreatic cancer mouse models [<xref ref-type="bibr" rid="bibr22-1758834012446008">Kano <italic>et al</italic>. 2007</xref>]. With this strategy they achieved reduction in the pericyte coverage of tumor vessels and therefore the enhancement of the accumulation of macromolecular nanomedicines in the area of the tumor. However, this strategy did not have any effect on the abundance of the fibrous elements of the pancreatic cancer models. More studies are needed to provide insight into the possible effect of such approaches in patients with pancreatic cancer. Finally, CD40 agonists activate the CD40 superfamily of tumor necrosis factor receptors and are associated with stroma shrinkage in pancreatic adenocarcinoma models in genetically engineered mice [<xref ref-type="bibr" rid="bibr3-1758834012446008">Beatty <italic>et al</italic>. 2011</xref>]. This effect was mediated by activation of the tumor-associated macrophages. Interestingly, in a primitive trial, CD40 agonist in combination with gemcitabine achieved a partial response to 4 out of 21 evaluable patients, further supporting the effectiveness of tumor immunity surveillance in the treatment of such tumors [<xref ref-type="bibr" rid="bibr3-1758834012446008">Beatty <italic>et al</italic>. 2011</xref>].</p>
</sec>
<sec id="section7-1758834012446008" sec-type="conclusions">
<title>Concluding remarks</title>
<p>There is a growing body of literature dealing with the optimization of drug delivery in pancreatic cancer. <xref ref-type="table" rid="table1-1758834012446008">Table 1</xref> summarizes relevant strategies currently in clinical trials in several pancreatic cancer settings. Given the special characteristics of this tumor type, it becomes plausible that the failure of clinical trials to show benefit from drug interventions might be a matter of poor drug accumulation at the sites of interest rather than endogenous antitumor drug activity. Incorporation of research biopsies and ‘mapping’ of the distribution of such anticancer drugs with novel imaging modalities is needed to establish the efficiency of drug delivery in relevant studies. We conclude that clinical trials that employ drug delivery optimization strategies like nanotechnology-based systems or stroma-depleting regimens are reasonable and promising.</p>
<table-wrap id="table1-1758834012446008" position="float">
<label>Table 1.</label>
<caption>
<p>Strategies for optimizing drug delivery in pancreatic cancer in clinical trials.</p>
</caption>
<graphic alternate-form-of="table1-1758834012446008" xlink:href="10.1177_1758834012446008-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Category</th>
<th align="left">Experimental drug</th>
<th align="left">Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conventional drugs embedded in nanoparticles</td>
<td>Nab-paclitaxel</td>
<td>Paclitaxel in albumin-bound nanoparticles</td>
</tr>
<tr>
<td/>
<td>PEP02</td>
<td>Liposomic CPT-11</td>
</tr>
<tr>
<td>siRNAs embedded in nanoparticles</td>
<td>CALAA 01</td>
<td>Nanoparticle that carries M2 subunit of ribonucleotide reductase (R2) siRNA</td>
</tr>
<tr>
<td/>
<td>siG12D LODER</td>
<td>Polymeric matrix that encompasses KRASG12D siRNA</td>
</tr>
<tr>
<td>Stromal-depleting drugs</td>
<td>IPI-926</td>
<td>Smoothened inhibitor</td>
</tr>
<tr>
<td/>
<td>GDC0449</td>
<td>Hedgehog inhibitor</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1758834012446008">
<p>siRNA, small interfering RNA.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare no conflict of interest in preparing this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Altenburg</surname><given-names>J.D.</given-names></name>
<name><surname>Bieberich</surname><given-names>A.A.</given-names></name>
<name><surname>Terry</surname><given-names>C.</given-names></name>
<name><surname>Harvey</surname><given-names>K.A.</given-names></name>
<name><surname>Vanhorn</surname><given-names>J.F.</given-names></name>
<name><surname>Xu</surname><given-names>Z.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone</article-title>. <source>BMC Cancer</source> <volume>11</volume>: <fpage>149</fpage>.</citation>
</ref>
<ref id="bibr2-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barth</surname><given-names>B.M.</given-names></name>
<name><surname>Sharma</surname><given-names>R.</given-names></name>
<name><surname>Altinoğlu</surname><given-names>E.I.</given-names></name>
<name><surname>Morgan</surname><given-names>T.T.</given-names></name>
<name><surname>Shanmugavelandy</surname><given-names>S.S.</given-names></name>
<name><surname>Kaiser</surname><given-names>J.M.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo</article-title>. <source>ACS Nano</source> <volume>4</volume>: <fpage>1279</fpage>–<lpage>1287</lpage>.</citation>
</ref>
<ref id="bibr3-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beatty</surname><given-names>G.L.</given-names></name>
<name><surname>Chiorean</surname><given-names>E.G.</given-names></name>
<name><surname>Fishman</surname><given-names>M.P.</given-names></name>
<name><surname>Saboury</surname><given-names>B.</given-names></name>
<name><surname>Teitelbaum</surname><given-names>U.R.</given-names></name>
<name><surname>Sun</surname><given-names>W.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans</article-title>. <source>Science</source> <volume>331</volume>: <fpage>1612</fpage>–<lpage>1616</lpage>.</citation>
</ref>
<ref id="bibr4-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berlin</surname><given-names>J.D.</given-names></name>
<name><surname>Catalano</surname><given-names>P.</given-names></name>
<name><surname>Thomas</surname><given-names>J.P.</given-names></name>
<name><surname>Kugler</surname><given-names>J.W.</given-names></name>
<name><surname>Haller</surname><given-names>D.G.</given-names></name>
<name><surname>Benson</surname><given-names>A.B.</given-names><suffix>3rd</suffix></name>
</person-group>. (<year>2002</year>) <article-title>Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297</article-title>. <source>J Clin Oncol</source> <volume>20</volume>: <fpage>3270</fpage>–<lpage>3275</lpage>.</citation>
</ref>
<ref id="bibr5-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhattacharyya</surname><given-names>S.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>R.</given-names></name>
<name><surname>Curley</surname><given-names>S.</given-names></name>
<name><surname>McNiven</surname><given-names>M.A.</given-names></name>
<name><surname>Mukherjee</surname><given-names>P.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>107</volume>: <fpage>14541</fpage>–<lpage>14546</lpage>.</citation>
</ref>
<ref id="bibr6-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bisht</surname><given-names>S.</given-names></name>
<name><surname>Feldmann</surname><given-names>G.</given-names></name>
<name><surname>Soni</surname><given-names>S.</given-names></name>
<name><surname>Ravi</surname><given-names>R.</given-names></name>
<name><surname>Karikar</surname><given-names>C.</given-names></name>
<name><surname>Maitra</surname><given-names>A.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Polymeric nanoparticle-encapsulated curcumin (‘nanocurcumin’): a novel strategy for human cancer therapy</article-title>. <source>J Nanobiotechnol</source> <volume>5</volume>: <fpage>3</fpage>.</citation>
</ref>
<ref id="bibr7-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brahimi-Horn</surname><given-names>M.C.</given-names></name>
<name><surname>Chiche</surname><given-names>J.</given-names></name>
<name><surname>Pouysségur</surname><given-names>J.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Hypoxia and cancer</article-title>. <source>J Mol Med</source> <volume>85</volume>: <fpage>1301</fpage>–<lpage>1307</lpage>.</citation>
</ref>
<ref id="bibr8-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chien</surname><given-names>A.J.</given-names></name>
<name><surname>Illi</surname><given-names>J.A.</given-names></name>
<name><surname>Ko</surname><given-names>A.H.</given-names></name>
<name><surname>Korn</surname><given-names>W.M.</given-names></name>
<name><surname>Fong</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>L.M.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies</article-title>. <source>Clin Cancer Res</source> <volume>15</volume>: <fpage>5569</fpage>–<lpage>5575</lpage>.</citation>
</ref>
<ref id="bibr9-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Conroy</surname><given-names>T.</given-names></name>
<name><surname>Desseigne</surname><given-names>F.</given-names></name>
<name><surname>Ychou</surname><given-names>M.</given-names></name>
<name><surname>Bouché</surname><given-names>O.</given-names></name>
<name><surname>Guimbaud</surname><given-names>R.</given-names></name>
<name><surname>Bécouarn</surname><given-names>Y.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer</article-title>. <source>N Engl J Med</source> <volume>364</volume>: <fpage>1817</fpage>–<lpage>1825</lpage>.</citation>
</ref>
<ref id="bibr10-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dancer</surname><given-names>J.</given-names></name>
<name><surname>Takei</surname><given-names>H.</given-names></name>
<name><surname>Ro</surname><given-names>J.Y.</given-names></name>
<name><surname>Lowery-Nordberg</surname><given-names>M.</given-names></name>
</person-group> (<year>2007</year>) <source>Oncol Rep</source> <volume>18</volume>: <fpage>151</fpage>–<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr11-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Di Costanzo</surname><given-names>F.</given-names></name>
<name><surname>Gasperoni</surname><given-names>S.</given-names></name>
<name><surname>Rotella</surname><given-names>V.</given-names></name>
<name><surname>Di Costanzo</surname><given-names>F.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer</article-title>. <source>Onco Targets Ther</source> <volume>2</volume>: <fpage>179</fpage>-<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr12-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drengler</surname><given-names>R.L.</given-names></name>
<name><surname>Smith</surname><given-names>L.S.</given-names></name>
<name><surname>Wood</surname><given-names>T.E.</given-names></name>
<name><surname>Borad</surname><given-names>M.J.</given-names></name>
<name><surname>Ramanathan</surname><given-names>R.K.</given-names></name>
<name><surname>Laheru</surname><given-names>D.A.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer</article-title>. <source>J Clin Oncol</source> <volume>26</volume> (<issue>15S</issue>): <comment>abstract 15523</comment>.</citation>
</ref>
<ref id="bibr13-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fasbender</surname><given-names>A.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<name><surname>Walters</surname><given-names>R.W.</given-names></name>
<name><surname>Moninger</surname><given-names>T.O.</given-names></name>
<name><surname>Zabner</surname><given-names>J.</given-names></name>
<name><surname>Welsh</surname><given-names>M.J.</given-names></name>
</person-group> (<year>1998</year>) <article-title>Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo</article-title>. <source>J Clin Invest</source> <volume>102</volume>: <fpage>184</fpage>–<lpage>193</lpage>.</citation>
</ref>
<ref id="bibr14-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garcea</surname><given-names>G.</given-names></name>
<name><surname>Jones</surname><given-names>D.J.</given-names></name>
<name><surname>Singh</surname><given-names>R.</given-names></name>
<name><surname>Dennison</surname><given-names>A.R.</given-names></name>
<name><surname>Farmer</surname><given-names>P.B.</given-names></name>
<name><surname>Sharma</surname><given-names>R.A.</given-names></name>
<etal/>
</person-group>. (<year>2004</year>) <article-title>Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration</article-title>. <source>Br J Cancer</source> <volume>90</volume>: <fpage>1011</fpage>–<lpage>1015</lpage>.</citation>
</ref>
<ref id="bibr15-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Glazer</surname><given-names>E.S.</given-names></name>
<name><surname>Zhu</surname><given-names>C.</given-names></name>
<name><surname>Massey</surname><given-names>K.L.</given-names></name>
<name><surname>Thompson</surname><given-names>C.S.</given-names></name>
<name><surname>Kaluarachchi</surname><given-names>W.D.</given-names></name>
<name><surname>Hamir</surname><given-names>A.N.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles</article-title>. <source>Clin Cancer Res</source> <volume>16</volume>: <fpage>5712</fpage>–<lpage>5721</lpage>.</citation>
</ref>
<ref id="bibr16-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hidalgo</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Pancreatic cancer</article-title>. <source>N Engl J Med</source> <volume>362</volume>: <fpage>1605</fpage>–<lpage>1617</lpage>.</citation>
</ref>
<ref id="bibr17-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hogrefe</surname><given-names>R.I.</given-names></name>
<name><surname>Lebedev</surname><given-names>A.V.</given-names></name>
<name><surname>Zon</surname><given-names>G.</given-names></name>
<name><surname>Pirollo</surname><given-names>K.F.</given-names></name>
<name><surname>Rait</surname><given-names>A.</given-names></name>
<name><surname>Zhou</surname><given-names>Q.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2</article-title>. <source>Nucleosides Nucleotides Nucleic Acids</source> <volume>25</volume>: <fpage>889</fpage>–<lpage>907</lpage>.</citation>
</ref>
<ref id="bibr18-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hosein</surname><given-names>P.J.</given-names></name>
<name><surname>de Lima Lopes</surname><given-names>G.</given-names><suffix>Jr</suffix></name>
<name><surname>Gomez</surname><given-names>C.M.</given-names></name>
<name><surname>Pastorini</surname><given-names>V.H.</given-names></name>
<name><surname>Macintyre</surname><given-names>J.</given-names></name>
<name><surname>Easey</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine (G)-based therapy</article-title>. <source>J Clin Oncol</source> <volume>28</volume> (<issue>15s</issue>): <comment>abstract 4120</comment>.</citation>
</ref>
<ref id="bibr19-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hu</surname><given-names>C.M.</given-names></name>
<name><surname>Kaushal</surname><given-names>S.</given-names></name>
<name><surname>Tran Cao</surname><given-names>H.S.</given-names></name>
<name><surname>Aryal</surname><given-names>S.</given-names></name>
<name><surname>Sartor</surname><given-names>M.</given-names></name>
<name><surname>Esener</surname><given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells</article-title>. <source>Mol Pharm</source> <volume>7</volume>: <fpage>914</fpage>–<lpage>920</lpage>.</citation>
</ref>
<ref id="bibr20-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ji</surname><given-names>R.C.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Characteristics of lymphatic endothelial cells in physiological and pathological conditions</article-title>. <source>Histol Histopathol</source> <volume>20</volume>: <fpage>155</fpage>–<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr21-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jutooru</surname><given-names>I.</given-names></name>
<name><surname>Chadalapaka</surname><given-names>G.</given-names></name>
<name><surname>Lei</surname><given-names>P.</given-names></name>
<name><surname>Safe</surname><given-names>S.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation</article-title>. <source>J Biol Chem</source> <volume>285</volume>: <fpage>25332</fpage>–<lpage>25344</lpage>.</citation>
</ref>
<ref id="bibr22-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kano</surname><given-names>M.R.</given-names></name>
<name><surname>Bae</surname><given-names>Y.</given-names></name>
<name><surname>Iwata</surname><given-names>C.</given-names></name>
<name><surname>Morishita</surname><given-names>Y.</given-names></name>
<name><surname>Yashiro</surname><given-names>M.</given-names></name>
<name><surname>Oka</surname><given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>104</volume>: <fpage>3460</fpage>–<lpage>3465</lpage>.</citation>
</ref>
<ref id="bibr23-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ko</surname><given-names>A.H.</given-names></name>
<name><surname>Tempero</surname><given-names>M.A.</given-names></name>
<name><surname>Shan</surname><given-names>Y.</given-names></name>
<name><surname>Su</surname><given-names>W.</given-names></name>
<name><surname>Lin</surname><given-names>Y.</given-names></name>
<name><surname>Dito</surname><given-names>E.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>A multinational phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer</article-title>. <source>J Clin Oncol</source> <volume>29</volume> (<issue>s4</issue>): <comment>abstract 237</comment>.</citation>
</ref>
<ref id="bibr24-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lu</surname><given-names>J.J.</given-names></name>
<name><surname>Cai</surname><given-names>Y.J.</given-names></name>
<name><surname>Ding</surname><given-names>J.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Curcumin induces DNA damage and caffeine-insensitive cell cycle arrest in colorectal carcinoma HCT116 cells</article-title>. <source>Mol Cell Biochem</source> <volume>354</volume>: <fpage>247</fpage>–<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr25-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luo</surname><given-names>G.</given-names></name>
<name><surname>Jin</surname><given-names>C.</given-names></name>
<name><surname>Long</surname><given-names>J.</given-names></name>
<name><surname>Fu</surname><given-names>D.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Xu</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles</article-title>. <source>Cancer Biol Ther</source> <volume>8</volume>: <fpage>594</fpage>–<lpage>598</lpage>.</citation>
</ref>
<ref id="bibr26-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luo</surname><given-names>G.</given-names></name>
<name><surname>Yu</surname><given-names>X.</given-names></name>
<name><surname>Jin</surname><given-names>C.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Fu</surname><given-names>D.</given-names></name>
<name><surname>Long</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors</article-title>. <source>Int J Pharm</source> <volume>38</volume>: <fpage>150</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr27-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maeda</surname><given-names>H.</given-names></name>
</person-group> (<year>2001</year>) <article-title>The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting</article-title>. <source>Adv Enzyme Regul</source> <volume>41</volume>: <fpage>189</fpage>–<lpage>207</lpage>.</citation>
</ref>
<ref id="bibr28-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murphy</surname><given-names>E.A.</given-names></name>
<name><surname>Majeti</surname><given-names>B.K.</given-names></name>
<name><surname>Barnes</surname><given-names>L.A.</given-names></name>
<name><surname>Makale</surname><given-names>M.</given-names></name>
<name><surname>Weis</surname><given-names>S.M.</given-names></name>
<name><surname>Lutu-Fuga</surname><given-names>K.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>105</volume>: <fpage>9343</fpage>–<lpage>9348</lpage>.</citation>
</ref>
<ref id="bibr29-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nagamitsu</surname><given-names>A.</given-names></name>
<name><surname>Greish</surname><given-names>K.</given-names></name>
<name><surname>Maeda</surname><given-names>H.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors</article-title>. <source>Jpn J Clin Oncol</source> <volume>39</volume>: <fpage>756</fpage>–<lpage>766</lpage>.</citation>
</ref>
<ref id="bibr30-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neesse</surname><given-names>A.</given-names></name>
<name><surname>Michl</surname><given-names>P.</given-names></name>
<name><surname>Frese</surname><given-names>K.K.</given-names></name>
<name><surname>Feig</surname><given-names>C.</given-names></name>
<name><surname>Cook</surname><given-names>N.</given-names></name>
<name><surname>Jacobetz</surname><given-names>M.A.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Stromal biology and therapy in pancreatic cancer</article-title>. <source>Gut</source> <volume>60</volume>: <fpage>861</fpage>–<lpage>868</lpage>.</citation>
</ref>
<ref id="bibr31-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olive</surname><given-names>K.P.</given-names></name>
<name><surname>Jacobetz</surname><given-names>M.A.</given-names></name>
<name><surname>Davidson</surname><given-names>C.J.</given-names></name>
<name><surname>Gopinathan</surname><given-names>A.</given-names></name>
<name><surname>McIntyre</surname><given-names>D.</given-names></name>
<name><surname>Honess</surname><given-names>D.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer</article-title>. <source>Science</source> <volume>324</volume>: <fpage>1457</fpage>–<lpage>1461</lpage>.</citation>
</ref>
<ref id="bibr32-1758834012446008">
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Palmer</surname><given-names>S.R.</given-names></name>
<name><surname>Erlichman</surname><given-names>C.</given-names></name>
<name><surname>Fernandez-Zapico</surname><given-names>M.</given-names></name>
<name><surname>Qi</surname><given-names>Y.</given-names></name>
<name><surname>Almada</surname><given-names>L.</given-names></name>
<name><surname>McCleary-Wheeler</surname><given-names>A.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449</article-title>. <conf-name>2011 ASCO Annual Meeting</conf-name>, <conf-date>1–5 June</conf-date>, <conf-loc>Chicago, IL, USA</conf-loc>.</citation>
</ref>
<ref id="bibr33-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patra</surname><given-names>C.R.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>E.</given-names></name>
<name><surname>Katarya</surname><given-names>A.</given-names></name>
<name><surname>Lau</surname><given-names>J.S.</given-names></name>
<name><surname>Dutta</surname><given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent</article-title>. <source>Cancer Res</source> <volume>68</volume>: <fpage>1970</fpage>–<lpage>1978</lpage>.</citation>
</ref>
<ref id="bibr34-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pittella</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Lee</surname><given-names>Y.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Tockary</surname><given-names>T.</given-names></name>
<name><surname>Osada</surname><given-names>K.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity</article-title>. <source>Biomaterials</source> <volume>32</volume>: <fpage>3106</fpage>–<lpage>3114</lpage>.</citation>
</ref>
<ref id="bibr35-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prencipe</surname><given-names>G.</given-names></name>
<name><surname>Tabakman</surname><given-names>S.M.</given-names></name>
<name><surname>Welsher</surname><given-names>K.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Goodwin</surname><given-names>A.P.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>PEG branched polymer for functionalization of nanomaterials with ultralong blood circulation</article-title>. <source>J Am Chem Soc</source> <volume>131</volume>: <fpage>4783</fpage>–<lpage>4787</lpage>.</citation>
</ref>
<ref id="bibr36-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Richards</surname><given-names>D.A.</given-names></name>
<name><surname>Stephenson</surname><given-names>J.</given-names></name>
<name><surname>Wolpin</surname><given-names>B.M.</given-names></name>
<name><surname>Becerra</surname><given-names>C.</given-names></name>
<name><surname>Hamm</surname><given-names>J.T.</given-names></name>
<name><surname>Messersmith</surname><given-names>W.A.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer</article-title>. <source>J Clin Oncol</source> <volume>30</volume> (<issue>s4</issue>): <comment>abstract 213</comment>.</citation>
</ref>
<ref id="bibr37-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rischin</surname><given-names>D.</given-names></name>
<name><surname>Webster</surname><given-names>L.K</given-names></name>
<name><surname>Millward</surname><given-names>M.J.</given-names></name>
<name><surname>Linahan</surname><given-names>B.M.</given-names></name>
<name><surname>Toner</surname><given-names>G.C.</given-names></name>
<name><surname>Woollett</surname><given-names>A.M.</given-names></name>
<etal/>
</person-group>. (<year>1996</year>) <article-title>Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel</article-title>. <source>J Natl Cancer Inst</source> <volume>88</volume>: <fpage>1297</fpage>–<lpage>1301</lpage>.</citation>
</ref>
<ref id="bibr38-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saito</surname><given-names>Y.</given-names></name>
<name><surname>Yasunaga</surname><given-names>M.</given-names></name>
<name><surname>Kuroda</surname><given-names>J.</given-names></name>
<name><surname>Koga</surname><given-names>Y.</given-names></name>
<name><surname>Matsumura</surname><given-names>Y.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor</article-title>. <source>Cancer Sci</source> <volume>99</volume>: <fpage>1258</fpage>–<lpage>1264</lpage>.</citation>
</ref>
<ref id="bibr39-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seki</surname><given-names>T.</given-names></name>
<name><surname>Fang</surname><given-names>J.</given-names></name>
<name><surname>Maeda</surname><given-names>H.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application</article-title>. <source>Cancer Sci</source> <volume>100</volume>: <fpage>2426</fpage>–<lpage>2430</lpage>.</citation>
</ref>
<ref id="bibr40-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Senderowicz</surname><given-names>A.M.</given-names></name>
<name><surname>Johnson</surname><given-names>J.R.</given-names></name>
<name><surname>Sridhara</surname><given-names>R.</given-names></name>
<name><surname>Zimmerman</surname><given-names>P.</given-names></name>
<name><surname>Justice</surname><given-names>R.</given-names></name>
<name><surname>Pazdur</surname><given-names>R.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas</article-title>. <source>Oncology (Williston Park)</source> <volume>21</volume>: <fpage>1696</fpage>–<lpage>1706</lpage>.</citation>
</ref>
<ref id="bibr41-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sugahara</surname><given-names>K.N.</given-names></name>
<name><surname>Teesalu</surname><given-names>T.</given-names></name>
<name><surname>Karmali</surname><given-names>P.P.</given-names></name>
<name><surname>Kotamraju</surname><given-names>V.R.</given-names></name>
<name><surname>Agemy</surname><given-names>L.</given-names></name>
<name><surname>Greenwald</surname><given-names>D.R.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs</article-title>. <source>Science</source> <volume>328</volume>: <fpage>1031</fpage>–<lpage>1035</lpage>.</citation>
</ref>
<ref id="bibr42-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Von Hoff</surname><given-names>D.D.</given-names></name>
<name><surname>Ramanathan</surname><given-names>R.K.</given-names></name>
<name><surname>Borad</surname><given-names>M.J.</given-names></name>
<name><surname>Laheru</surname><given-names>D.A.</given-names></name>
<name><surname>Smith</surname><given-names>L.S.</given-names></name>
<name><surname>Wood</surname><given-names>T.E.</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial</article-title>. <source>J Clin Oncol</source> <volume>29</volume>: <fpage>4548</fpage>–<lpage>4554</lpage>.</citation>
</ref>
<ref id="bibr43-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weissleder</surname><given-names>R.</given-names></name>
<name><surname>Kelly</surname><given-names>K.</given-names></name>
<name><surname>Sun</surname><given-names>E.Y.</given-names></name>
<name><surname>Shtatland</surname><given-names>T.</given-names></name>
<name><surname>Josephson</surname><given-names>L.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Cell-specific targeting of nanoparticles by multivalent attachment of small molecules</article-title>. <source>Nat Biotechnol</source> <volume>23</volume>: <fpage>1418</fpage>–<lpage>1423</lpage>.</citation>
</ref>
<ref id="bibr44-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xia</surname><given-names>T.</given-names></name>
<name><surname>Kovochich</surname><given-names>M.</given-names></name>
<name><surname>Liong</surname><given-names>M.</given-names></name>
<name><surname>Meng</surname><given-names>H.</given-names></name>
<name><surname>Kabehie</surname><given-names>S.</given-names></name>
<name><surname>George</surname><given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs</article-title>. <source>ACS Nano</source> <volume>3</volume>: <fpage>3273</fpage>–<lpage>3286</lpage>.</citation>
</ref>
<ref id="bibr45-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yauch</surname><given-names>R.L.</given-names></name>
<name><surname>Gould</surname><given-names>S.E.</given-names></name>
<name><surname>Scales</surname><given-names>S.J.</given-names></name>
<name><surname>Tang</surname><given-names>T.</given-names></name>
<name><surname>Tian</surname><given-names>H.</given-names></name>
<name><surname>Ahn</surname><given-names>C.P.</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>A paracrine requirement for hedgehog signalling in cancer</article-title>. <source>Nature</source> <volume>455</volume>: <fpage>406</fpage>–<lpage>410</lpage>.</citation>
</ref>
<ref id="bibr46-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Youns</surname><given-names>M.</given-names></name>
<name><surname>Hoheisel</surname><given-names>J.D.</given-names></name>
<name><surname>Efferth</surname><given-names>T.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Therapeutic and diagnostic applications of nanoparticles</article-title>. <source>Curr Drug Targets</source> <volume>12</volume>: <fpage>357</fpage>–<lpage>365</lpage>.</citation>
</ref>
<ref id="bibr47-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yuan</surname><given-names>F.</given-names></name>
<name><surname>Dellian</surname><given-names>M.</given-names></name>
<name><surname>Fukumura</surname><given-names>D.</given-names></name>
<name><surname>Leunig</surname><given-names>M.</given-names></name>
<name><surname>Berk</surname><given-names>D.A.</given-names></name>
<name><surname>Torchilin</surname><given-names>V.P.</given-names></name>
<etal/>
</person-group>. (<year>1995</year>) <article-title>Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size</article-title>. <source>Cancer Res</source> <volume>55</volume>: <fpage>3752</fpage>–<lpage>3756</lpage>.</citation>
</ref>
<ref id="bibr48-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Koh</surname><given-names>G.Y.</given-names></name>
<name><surname>Jeansonne</surname><given-names>D.P.</given-names></name>
<name><surname>Hollingsworth</surname><given-names>J.</given-names></name>
<name><surname>Russo</surname><given-names>P.S.</given-names></name>
<name><surname>Vicente</surname><given-names>G.</given-names></name>
<etal/>
</person-group>. (<year>2001</year>) <article-title>A novel solubility-enhanced curcumin formulation showing stability and maintenance of anticancer activity</article-title>. <source>J Pharm Sci</source> <volume>100</volume>: <fpage>2778</fpage>–<lpage>2789</lpage>.</citation>
</ref>
<ref id="bibr49-1758834012446008">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Du</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>C.</given-names></name>
<name><surname>Ren</surname><given-names>X.</given-names></name>
<name><surname>Ti</surname><given-names>X.</given-names></name>
<name><surname>Shi</surname><given-names>J.</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186* signaling pathway</article-title>. <source>Oncol Rep</source> <volume>24</volume>: <fpage>1217</fpage>–<lpage>1223</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>